跳至主要内容
临床试验/NCT04458194
NCT04458194进行中(未招募)不适用

A Feasibility Trial Comparing the Effectiveness of Virtual YOCAS©® Yoga to Standard Care for Treating Insomnia in Cancer Survivors

University of Rochester2 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2022年1月12日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
42
试验地点
2
主要终点
Mean change in insomnia as measured by the Insomnia Severity Index (ISI) total score comparing cancer survivors in YOCAS vs. Standard Care

研究概览

简要总结

This feasibility phase II randomized controlled trial examines the preliminary efficacy of our standardized four-week YOCAS©® (Yoga for Cancer Survivors) intervention that is delivered virtually on insomnia and sleep quality in cancer survivors.

Insomnia can be described as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, or waking up earlier than desired. The vast majority of patients with cancer experience some form of sleep impairment post-treatment. Yoga is safe, feasible, and effective for improving insomnia and sleep quality in cancer survivors. However, most of the yoga intervention was delivered in person. With the challenges and the social distancing regulation regarding the COVID-19 pandemic, adapting to virtual behavioral intervention is critically important and needed. Whether the yoga intervention delivered virtually to survivors provides a similar benefit of improving insomnia and sleep quality is unknown.

详细描述

PRIMARY OBJECTIVE:

To compare the effects of virtual YOCAS©® intervention to standard care on changes in insomnia measured via the Insomnia Severity Index among cancer survivors

SECONDARY OBJECTIVE:

To compare the effects of virtual YOCAS©® intervention to standard care on changes in sleep quality measured via the Pittsburgh Sleep Quality Index among cancer survivors

OUTLINE: Cancer survivors are randomized to 1 of 2 arms.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Cancer Survivors must:
  • •have a confirmed diagnosis of cancer
  • •have received surgery, chemotherapy, and/or radiation therapy
  • •have completed all surgery, chemotherapy, and/or radiation therapy within the last 2 months to 10 years
  • •score ≥4 on a 0-10 sleep screening scale
  • •be at least 18 years of age
  • •be able to read and understand English
  • •be able to provide informed consent
  • •have access to the internet and a smartphone, tablet, and/or computer
  • •have the ability to attend 8 virtual yoga sessions

排除标准

  • •Cancer Survivor must not:
  • •have contraindications to yoga participation
  • •have practiced yoga within the 3 months prior to enrolling in the study
  • •be planning to start yoga on their own during the time they are enrolled in the study
  • •have a confirmed diagnosis of sleep apnea or restless leg syndrome
  • •be receiving any form of treatment for cancer with the exception of hormonal or biologic therapy
  • •have distant metastases

研究组 & 干预措施

Standard Care

Active Comparator

Cancer survivors receive their standard care

干预措施: Standard Care (Other)

YOCAS

Experimental

Cancer survivors receive 8 virtual yoga sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via an electronic platform (e.g., Zoom)

干预措施: YOCAS©® yoga (Behavioral)

结局指标

主要结局

Mean change in insomnia as measured by the Insomnia Severity Index (ISI) total score comparing cancer survivors in YOCAS vs. Standard Care

时间窗: baseline to week 5

The Insomnia Severity Index is a validated measure of insomnia. A 5-point Likert scale of 7 questions is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28 with higher scores indicating higher severity of insomnia. A linear mixed effects ANCOVA will be used to assess the statistical significance of the differences in mean change among cancer survivors in YOCAS vs. Standard Care

次要结局

  • Mean Change in sleep quality as measured by the Pittsburgh Sleep Quality Inventory (PSQI) total Score comparing cancer survivors in YOCAS vs. Standard Care(baseline to week 5)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Karen Mustian

Professor

University of Rochester

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
1 期
A study with the aim to evaluate the antitumor activity of a new association of oral drugs, lenalidomide and clarithromycin in patients with lymphoma (MALT), when standard treatment with radiation therapy, chemotherapy and / or immunotherapy have shown a lack of efficacy.Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy.MedDRA version: 21.0Level: PTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10015824Term: Extranodal marginal zone B-cell lymphoma (MALT type) refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003168-35-ITIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP68
进行中(未招募)
1 期
A phase II trial clarithromycin + lenalidomide combination:for patients with relapsed/refractory extranodal marginal zone lymphomaextranodal marginal zone lymphoma (MALT)
EUCTR2015-003168-35-ATIELSG International Extranodale Lymphoma Study Group; Instituto Oncologico della Svizzera Italiana,68
已完成
不适用
Testing the Feasibility and Preliminary Effect of Summer CampChildhood Obesity Prevention
NCT04085965The Miriam Hospital94
尚未招募
不适用
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL: FL grade 3b and DLBC
NL-OMON24909Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl60
招募中
不适用
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation.Recurrent aggressive B-cell lymphoma with CNS localisation, DLBCL, non-hodgkin lymphoma, NH
NL-OMON23427Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl35
Comparing Virtual Yoga to Standard Care on Insomnia... | 临床试验